10-Q: Philip Morris International Reports Strong Q3 2025 Growth

Philip Morris International reports significant revenue and earnings growth for the third quarter and first nine months of 2025, driven by strong smoke-free product performance despite ongoing litigation and restructuring charges.

Summary

• Net revenues for the nine months ended September 30, 2025, increased by 7.5% to $30.3 billion, compared to $28.2 billion in 2024.
• Diluted earnings per share (EPS) for the nine months ended September 30, 2025, increased by 20.4% to $5.89, up from $4.89 in 2024.
• Net revenues for the three months ended September 30, 2025, increased by 9.4% to $10.8 billion, compared to $9.9 billion in 2024.
• Diluted EPS for the three months ended September 30, 2025, increased by 13.2% to $2.23, up from $1.97 in 2024.
• Smoke-free product (SFP) volumes increased by 14.3% for the nine months and 16.6% for the three months, with all SFP categories showing strong growth.
• Cigarette volumes decreased by 1.3% for the nine months and 3.2% for the three months.
• Operating income for the nine months increased by 13.6% to $11.5 billion, and for the three months by 16.7% to $4.3 billion.
• The effective tax rate decreased to 19.2% for the nine months and 18.7% for the three months, favorably impacted by deferred tax benefits and refunds.
• A goodwill impairment charge of $41 million was recorded in the Europe segment during the second quarter of 2025.
• Restructuring charges of $243 million were recorded in 2025, primarily related to ending combustible tobacco production in two German factories.
• A $176 million pre-tax charge was recorded in Q3 2025 related to the Germany excise tax classification litigation for TEREA consumables.
• The RBH (Canada) Plan implementation resulted in after-tax income of $156 million, including a $303 million dividend, net of a $166 million income tax charge.
• A non-cash after-tax impairment charge of $146 million was recorded for a Wellness & Healthcare related equity investment in Q3 2025.
• Net cash provided by operating activities for the nine months was $7.5 billion, down from $8.2 billion in 2024, primarily due to higher working capital requirements.
• Total debt stood at $50.1 billion at September 30, 2025, up from $45.7 billion at December 31, 2024.

Sentiment

Score: 8

Explanation: The company demonstrated strong financial performance with significant increases in net revenues and diluted EPS, primarily driven by robust growth in smoke-free products. While there were notable charges from goodwill impairment, restructuring, and litigation, these were largely offset by operational gains and favorable tax impacts. The resolution of the Canadian CCAA plan and FDA authorizations for ZYN are positive developments. The future outlook for smoke-free products remains strong, despite expected declines in combustible tobacco and ongoing litigation risks.

Positives

• Net revenues increased by 7.5% for the nine months and 9.4% for the three months ended September 30, 2025, driven by favorable pricing and smoke-free product volume growth.
• Diluted EPS increased by 20.4% for the nine months and 13.2% for the three months, reflecting strong operational performance.
• Smoke-free product volumes grew significantly by 14.3% (nine months) and 16.6% (three months), indicating successful transition efforts.
• Operating income increased by 13.6% for the nine months and 16.7% for the three months, demonstrating improved profitability.
• Effective tax rates decreased to 19.2% (nine months) and 18.7% (three months), positively impacting net earnings.
• The resolution of Canadian tobacco claims under the RBH (Canada) Plan resulted in a $303 million dividend income to PMI.
• Successful reacquisition of IQOS commercialization rights in the U.S. from Altria Group, Inc., effective May 2024, with initial sales of IQOS 3.0 in Austin, Texas.
• FDA authorized all 20 ZYN nicotine pouch varieties for sale in the U.S. on January 16, 2025, recognizing their lower risk profile compared to cigarettes and most smokeless tobacco products.
• The Supreme Court of Thailand reduced the customs duty fine to $0.6 million, requiring a refund of the excess payment made by the subsidiary.
• Japan patent infringement actions against Sojitz for TEREA consumables were terminated in September 2025 after the Tokyo District Court indicated non-infringement.

Negatives

• Cigarette volumes continued to decline by 1.3% for the nine months and 3.2% for the three months, reflecting ongoing market contraction.
• A goodwill impairment charge of $41 million was recorded in the Europe segment in Q2 2025.
• Restructuring charges of $243 million were incurred in 2025, primarily due to the closure of two German combustible tobacco factories.
• A $176 million pre-tax charge was recorded in Q3 2025 for the Germany excise tax classification litigation related to TEREA consumables.
• A non-cash after-tax impairment charge of $146 million was recorded for a Wellness & Healthcare related equity investment in Q3 2025 due to a reassessment of fair value.
• Net cash provided by operating activities decreased by $0.7 billion for the nine months, primarily due to higher working capital requirements.
• Total debt increased to $50.1 billion at September 30, 2025, from $45.7 billion at December 31, 2024.
• Ongoing ZYN nicotine pouch litigation in the U.S. includes multiple class actions and individual complaints alleging addiction, defective design, and misleading marketing.

Risks

• Unsuccessful introduction, commercialization, and growth of smoke-free products in existing and new markets, or regulatory prohibitions/restrictions on these products.
• Inequitable regulation of heat-not-burn products compared to other SFP categories, leading to a competitive disadvantage.
• Negative public opinion or mischaracterization of SFPs due to inappropriate marketing by other market participants or alleged health consequences of e-vapor products.
• Significant usage of products among youth or non-nicotine users, leading to reputational damage, more restrictive regulation, and hindered advocacy efforts.
• Adverse impact from federal, state, or local government actions in the U.S., including regulatory actions or inaction by the FDA, on SFP commercialization.
• Lower predictability of financial and business performance for smoke-free products compared to the mature cigarette business.
• Inability to differentiate smoke-free products and cigarettes with respect to taxation, potentially leading to higher tax rates and reduced SFP unit margins.
• Continued decline in consumption of tax-paid cigarettes due to increased taxes, governmental actions, diminishing social acceptance, health concerns, competition, economic uncertainty, and illicit products.
• Significant governmental action aimed at increasing regulatory requirements for tobacco/nicotine products, including bans on advertising, plain packaging, ingredient restrictions (e.g., menthol), and generation sales bans.
• Variability in effective tax rates due to changes in earnings mix, tax laws (e.g., OECD's Pillar Two), or punitive tax legislation related to doing business in Russia.
• Restrictions on receiving payments from foreign subsidiaries or repatriating royalties and dividends due to local currency exchange controls and other regulations.
• Disruptions in credit markets or changes to credit ratings adversely affecting borrowing costs and financial condition.
• Product recalls due to quality/safety failures, contamination, or manufacturing defects, leading to adverse business, reputational, and financial impacts.
• Inability to adequately protect intellectual property rights or claims of infringement by third parties, leading to litigation costs and impeded product development.
• Legal, regulatory, and reputational risks associated with the research, development, and commercialization of non-recreational cannabinoid products.
• Intense competition from other tobacco companies and new market entrants, potentially leading to reduced profitability.
• Inability to anticipate changes in adult consumer preferences, impacting brand equity, new product development, and profitability.
• Limitations on profit growth due to inability to introduce new products, enter new markets, maintain sufficient production capacity, or improve margins.
• Failure to successfully identify, complete, or realize benefits from strategic acquisitions, divestitures, joint ventures, or investments.
• Inability to attract, motivate, and retain global talent, particularly in new areas like digital and life sciences.
• Adverse impact on revenues from counterfeiting, contraband, cross-border purchases, illicit products, and non-tax-paid volume.
• Cybersecurity incidents or attacks on information technology networks and systems, or those of third parties, leading to business disruption, data breaches, and financial/reputational harm.
• Failure to adhere to privacy, data, artificial intelligence, and information security laws, resulting in legal liability, reputational damage, and financial penalties.
• Risks associated with the use of artificial intelligence-based solutions, including flaws, biases, system failures, and exacerbation of other risks.
• Adverse impact from the continuation and consequences of the war in Ukraine, including potential impairment of Russian assets, supply chain disruptions, and increased operating costs.
• Negative impact from the effects of climate change, other environmental issues, and related legal or regulatory responses on agricultural products, operations, and compliance costs.
• Government mandated prices, production control programs, and shifts in crops increasing the cost or reducing the quality of tobacco and other agricultural products.
• Prolonged disruption of production facilities, especially the ZYN production facility in Kentucky, U.S., limiting capacity and impacting market share.

Future Outlook

Philip Morris International expects total international industry volume for cigarettes and heated tobacco units (excluding China and the U.S.) to decline by approximately 1% for the full year 2025. Total PMI cigarette and smoke-free product shipment volume is projected to grow by around 1%, with smoke-free product volume growth of 12% to 14% (likely in the lower half of this range) and cigarette volume declines of around 2%. Net cash provided by operating activities is anticipated to exceed $11.5 billion for the full year 2025, subject to year-end working capital requirements. Total capital expenditures in 2025 are expected to be around $1.6 billion, primarily supporting the smoke-free business. The global tariff environment is expected to remain volatile throughout 2025 and 2026.

Management Comments

• Our key strategic priorities are to continue developing and commercializing products that have the potential to present less risk of harm to adult smokers who switch to such products versus continued cigarette smoking, and to educate and encourage current adult smokers who would otherwise continue to smoke cigarettes to switch to those products.
• We believe that when better alternatives to cigarettes exist, the discussion should not be whether these alternatives should be made available to the more than one billion people who smoke cigarettes today, but how fast they can be made available, and within what regulatory framework to maximize their adoption by adult smokers while minimizing unintended use.
• We advocate for regulatory frameworks that are based on a continuum of risk where non-combustible products fall below combustible cigarettes, and that regulation and taxation should differentiate between cigarettes and products that present less risk of harm.
• We anticipate a 20 to 30 million can inventory reduction in the coming months for U.S. nicotine pouches, this impact being effectively delayed from the third quarter given strong September promotional activity.
• We expect that the combination of our long-term and short-term debt financing, the commercial paper program and the committed credit facilities, coupled with our operating cash flows, will enable us to meet our liquidity requirements.

Industry Context

The tobacco industry continues its global transformation towards smoke-free products, driven by health concerns and evolving regulatory landscapes. PMI is actively leading this transition, investing heavily in R&D and commercialization of products like IQOS and ZYN. While combustible tobacco consumption declines globally, the smoke-free category is experiencing significant growth, with regulatory bodies like the FDA increasingly recognizing the harm-reduction potential of these products. However, the industry faces ongoing challenges from stringent regulations, high excise taxes, illicit trade, and a complex, evolving legal environment, particularly concerning novel nicotine products. The war in Ukraine and global inflationary pressures also continue to impact supply chains and operating costs across the sector.

Comparison to Industry Standards

• PMI's smoke-free product volume growth of 14.3% (nine months) and 16.6% (three months) demonstrates strong performance in a rapidly expanding category, aligning with the industry's shift towards reduced-risk alternatives.
• The FDA's authorization of 20 ZYN nicotine pouch varieties and the Modified Risk Tobacco Product (MRTP) orders for IQOS products position PMI favorably against competitors by providing scientifically substantiated claims, a key differentiator in the evolving nicotine market.
• The estimated total international industry volume decline of around 1% for cigarettes and HTUs for the full year 2025 indicates a challenging environment for traditional tobacco products, which PMI is mitigating through its smoke-free portfolio growth.
• PMI's strategy of reallocating resources from cigarettes to SFPs and streamlining its cigarette portfolio is consistent with broader industry trends where companies like British American Tobacco (BAT) and Japan Tobacco (JT) are also investing in next-generation products to offset declining cigarette sales.

Corporate Governance

Legal Proceedings

• The Canadian CCAA Plan was implemented on August 29, 2025, resolving all outstanding objections and releasing RBH and its affiliates (including PMI) from claims related to combustible tobacco products prior to the effective date. RBH paid a dividend of CAD $750 million to PMI.
• Multiple putative class actions and individual complaints have been filed in U.S. federal courts (e.g., Kelly, Palmer, Lendinara, Friedman, Norris, Maultsby, Dykes, Siegert) against PMI and Swedish Match subsidiaries related to ZYN nicotine pouches, alleging addiction, defective design, misleading marketing, and consumer protection violations. Several cases are in the discovery phase, with trial dates set for December 2026 in Florida cases.
• The Mayor and City Council of Baltimore filed a case against PMI and Swedish Match subsidiaries in May 2025, alleging deceptive marketing of ZYN products in violation of the city's Consumer Protection Ordinance.
• The antitrust class action Neumark v. Swedish Match North America LLC was dismissed with prejudice by the U.S. District Court for the Eastern District of Virginia on September 18, 2025.
• The Supreme Court of Thailand issued a decision on October 9, 2025, in the customs duties and excise taxes case, reducing the fine to THB 20 million (approximately $0.6 million) and requiring a refund of the excess payment.
• An anti-corruption investigation by the Public Prosecutors office of Rome, Italy, against Philip Morris Italia S.r.l. and individuals is ongoing, with trial expected to continue through 2025. British American Tobacco Italia S.p.a. is seeking EUR50 million in damages.
• The Brazilian Tax Authority issued assessments in December 2024 and March 2025 alleging underpayments of indirect taxes for 2020 and 2021, totaling approximately $66 million, with further assessments expected for subsequent years.
• The Germany excise tax classification litigation for TEREA consumables resulted in a $176 million pre-tax charge in Q3 2025 after PM Germany withdrew its appeal, following a decision by the Fiscal Court Dsseldorf.
• Multiple new patent infringement actions were filed by Future Technology K.K. (FTKK) against Sojitz (PMJL's importer/distributor) between November 2024 and July 2025, alleging infringement of nine new FTKK patents by TEREA and SENTIA consumables. PMJL is obligated to indemnify Sojitz.

Related Party Transactions

• Net revenues from related parties were $3,387 million for the nine months ended September 30, 2025, and $1,307 million for the three months ended September 30, 2025.
• Related party receivables were $905 million at September 30, 2025, including $607 million from Megapolis Group and $298 million from other related parties.
• Related party payables were $35 million at September 30, 2025.
• PMI holds a 23% equity interest in JSC TK Megapolis (TKM), its distributor in Russia, with a carrying value of $305 million at September 30, 2025.
• PMI holds a 49% equity interest in Emirati Investors-TA (FZC) (EITA) and an approximate 25% economic interest in Socit des Tabacs Algro-Emiratie (STAEM).
• PMI acquired a controlling interest of 54.25% in United Tobacco Company (UTC) in May 2024.
• PMI acquired an indirect economic interest of 14.7% in Eastern Company in May 2024 and guaranteed certain credit facilities up to $385 million.
• Transactions with related parties are primarily for distribution, service fees, contract manufacturing, and license agreements.

Stakeholder Impact

• **Shareholders:** Positive impact from increased diluted EPS and dividend increase (8.9% to $1.47 per common share), but potential negative impact from increased debt and ongoing litigation risks.
• **Employees:** Impacted by restructuring activities, such as the closure of German factories, leading to employee separation costs. New production facility in Ukraine provides employment opportunities.
• **Customers:** Continued focus on providing a portfolio of smoke-free products as alternatives to cigarettes. Availability of ZYN nicotine pouches in the U.S. is enhanced. Potential for disruption from illicit trade.
• **Suppliers:** Supply chain financing program offers flexibility. Potential for disruption due to geopolitical events (e.g., Ukraine war) and global tariff volatility.
• **Creditors:** Increased total debt, but strong operating cash flows and committed credit facilities are expected to meet liquidity requirements. Credit ratings remain stable or positive from major agencies.

Next Steps

• Realign reportable segments into International Smoke-Free, International Combustibles, and U.S. business units, effective January 1, 2026.
• Report financial results based on the new segments as of the first quarter of 2026.
• Continue to pursue a limited U.S. roll-out of the IQOS device while waiting for authorization to market IQOS ILUMA, the induction version, in the United States.
• FDA Tobacco Product Scientific Advisory Committee (TPSAC) is expected to meet in the first quarter of 2026 regarding ZYN MRTPAs.
• Monitor developments in the EU market regarding the ban on characterizing flavors in heated tobacco products, including from an illicit trade standpoint.
• Continue to evaluate and monitor additional guidance and clarification regarding the OECD's Pillar Two global minimum tax framework.
• Continue to monitor the global tariff environment, which is expected to remain volatile throughout 2025 and 2026.
• Continue to assess the evolving situation in Russia, including regulatory constraints for any divestment transaction.

Key Dates

Recommendation

Philip Morris International demonstrates strong financial performance with significant growth in net revenues and diluted EPS, primarily driven by its successful transition to smoke-free products. The FDA authorizations for ZYN and IQOS provide a clear regulatory pathway and competitive advantage in the reduced-risk product category. However, the company faces substantial headwinds including declining combustible tobacco volumes, significant restructuring charges, ongoing and new litigation related to ZYN, and geopolitical risks in Russia and Ukraine. While the dividend increase is positive for income investors, the increased debt levels and the inherent uncertainties of a transforming industry, coupled with legal and regulatory challenges, suggest a 'hold' recommendation. Investors should monitor the progress of smoke-free product adoption, the outcomes of key litigations, and the impact of global economic and regulatory changes.

Keywords

Philip Morris International, PMI, SEC Filing, 10-Q, Quarterly Report, Financial Results, Earnings, Revenue, Smoke-Free Products, IQOS, ZYN, Nicotine Pouches, Heated Tobacco Units, Combustible Tobacco, Litigation, Regulatory Environment, Dividend, Capital Expenditures, Debt, Goodwill Impairment, Restructuring, Taxation, Russia, Ukraine, Sweden Match, Altria, FDA, MRTP, ESG, Sustainability